Bosutinib

Recent Results in Cancer Research

Volumn 184, Issue , 2010, Pages 119-127

  Brümmendorf, Tim H ^a   Keller, Gunhild ^b   Schafhausen, Philippe ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; BOSUTINIB; DASATINIB; GIERECC; NILOTINIB; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE LYMPHOCYTIC LEUKEMIA; ANEMIA; BLAST CELL CRISIS; BREAST CANCER; CELL NUCLEUS; CELL PROLIFERATION; CHROMOSOME 22; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CYTOGENETICS; CYTOPLASM; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; FEVER; FLUID RETENTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTERFEROMETER; LEUKEMIA RELAPSE; LUNG NON SMALL CELL CANCER; METASTASIS; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RASH; REVIEW; SIDE EFFECT; SOLID TUMOR; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ANILINE COMPOUNDS; ANIMALS; CLINICAL TRIALS AS TOPIC; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASMS; NITRILES; ONCOGENE PROTEINS V-ABL; PROTEIN KINASE INHIBITORS; QUINOLINES;

EID: 77953681442     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-01222-8_9     Document Type: Review

References (26)

1. Boschelli DH, Ye F et al (2001) Optimization of 4-phenylamino-3- quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 44(23):3965-3977 (Pubitemid 33051486)
2. Bruemmendorf TH, Cervantes F, et al (2008) Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. J Clin Oncol 26(Suppl):abstr. 7001
3. Chung SW, Daniel R et al (1996) The ABL genes in normal and abnormal cell development. Crit Rev Oncog 7(1-2):33-48
4. Coluccia AM, Benati D et al (2006) SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp 60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res 66(4): 2279-2286
5. Donato NJ, Wu JY et al (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101(2):690-698
6. Gambacorti-Passerini C, Kantarjian HM, et al (2008) Activity and tolerance of bosutinib in patients with AP and BP CML and Ph+ ALL. J Clin Oncol 26 May 20 (Suppl):abstr. 7049
7. Golas JM, Arndt K et al (2003) SKI-606, a 4-anilino-3- quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63(2):375-381
8. Golas JM, Lucas J et al (2005) SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 65(12):5358-5364
9. Hu Y, Swerdlow S et al (2006) Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A 103(45):16870-16875
10. Jallal H, Valentino ML et al (2007) A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res 67(4):1580-1588
11. Johnson FM, Gallick GE (2007) SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 7(6):651-659
12. Laneuville P (1995) Abl tyrosine protein kinase. Semin Immunol 7(4):255-266
13. Li S (2008) Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 49(1): 19-26
14. Lutz MP, Esser IB et al (1998) Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 243(2):503-508
15. Mazurenko NN, Kogan EA et al (1992) Expression of pp 60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer 28(2-3): 372-377
16. Messersmith WA, Krishnamurthi S, Hewes BA, Zacharchuk CM, Abbas R, Martins P, Dowling E, Volkert A, Martin E, Daud AI (2007) Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: preliminary results from a phase 1 study in patients with advanced malignant solid tumors. J Clin Oncol 25:abstr. 3552
17. Ottenhoff-Kalff AE, Rijksen G et al (1992) Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 52(17):4773-4778
18. Pendergast AM (1996) Nuclear tyrosine kinases: from Abl to WEE1. Curr Opin Cell Biol 8(2): 174-181
19. Ptasznik A, Nakata Y et al (2004) Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCRABL1(+) leukemia cells. Nat Med 10(11): 1187-1189
20. Puttini M, Coluccia AM et al (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 66(23): 11314-11322
21. Sattler M, Griffin JD (2003) Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 40(2 Suppl 2):4-10
22. Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22(4):337-358
23. Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513-609
24. Verbeek BS, Vroom TM et al (1996) c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 180(4):383-388
25. Vultur A, Buettner R et al (2008) SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 7(5):1185-1194
26. Zhang J, Kalyankrishna S et al (2007) SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 170(1):366-376